Skip to main content
Premium Trial:

Request an Annual Quote

Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform

NEW YORK – Myriad Genetics and Lumea said Wednesday that they will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.

The deal aims to simplify workflows for physicians by streamlining the ordering and delivery of these genetic assays. Providers will be able to order and track the Prolaris and MyRisk tests electronically and receive results directly through BxLink. The collaborators expect the automated process to reduce errors and deliver results to clinicians within roughly 10 days from sample collection.

"This collaboration with Lumea ensures precision-based insights are delivered in a timely fashion when they’re needed most to empower patients and providers to make informed decisions," George Daneker, president and chief clinical officer of oncology at Myriad, said in a statement.

Lehi, Utah-based Lumea signed a similar agreement with Caris Life Sciences last year, under which it is offering Caris' molecular profiling services for urological cancers through its BxLink platform.